Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receiv

Trial Details

NCT ID
NCT07195695
Phase
PHASE3
Sponsor
Boehringer Ingelheim
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Zongertinib
  • Pembrolizumab
  • Atezolizumab
  • Durvalumab
  • Nivolumab
Locations (sample)
  • Fresno, California, United States|36.74773,-119.77237
  • Glendale, California, United States|34.14251,-118.25508
  • Irvine, California, United States|33.66946,-117.82311
  • Roseville, California, United States|38.75212,-121.28801
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
  • Patients must be ≥18 years old or over the legal age of consent in their country
  • Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use dual highly effective methods of birth control per I…
  • HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor receptor 2 (HER2) mutations

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →